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Abstract  
Warburg’s observation that cancer cells exhibit a high rate of glycolysis even in the 
presence of oxygen (aerobic glycolysis) sparked debate over the role of glycolysis in normal and 
cancer cells.  While it has been established that defects in mitochondrial respiration is not the 
cause of cancer or aerobic glycolysis, the advantages of enhanced glycolysis in cancer remain 
controversial.  Many cells ranging from microbes to lymphocytes use aerobic glycolysis during 
rapid proliferation, suggesting it may play a fundamental role in supporting cell growth.  Here, 
we review how glycolysis contributes to the metabolic processes of dividing cells.  We provide a 
detailed accounting of the biosynthetic requirements to construct a new cell, and illustrate the 
importance of glycolysis in providing carbons to generate biomass.  We argue that the major 
function of aerobic glycolysis is to maintain high levels of glycolytic intermediates to support 
anabolic reactions in cells, providing an explanation for why increased glucose metabolism is 
selected in proliferating cells throughout nature. 
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Introduction 
All cells need a source of energy to maintain homeostasis.  Cellular maintenance involves 
non-spontaneous, energy-consuming processes such as generation of concentration gradients, 
cytoskeletal dynamics, DNA repair, basal transcription and translation, protein turnover, and 
vesicle trafficking.  The laws of thermodynamics mandate a continuous inflow of energy to 
balance these enthalpic (positive) and entropic (negative) requirements of cell maintenance, and 
cells must therefore extract free energy from nutrients or sunlight.  While maintaining 
homeostasis, proliferating cells have additional energetic requirements to grow and divide.  
Thus, proliferating cells must acquire more nutrients, convert them into biosynthetic building 
blocks, and coordinate the reactions necessary to transform them into macromolecules essential 
for constructing a new cell.  We have yet to fully understand how cells regulate biochemical 
pathways to: 1) allocate nutrients to provide free energy, mostly in the form of ATP, to allow 
otherwise unfavorable biochemical reactions; and 2) fuel the anabolic processes needed to grow 
and make new cells.  By definition, cancer involves the inappropriate proliferation of cells, and 
the metabolic phenotype of cancer cells must represent a solution to how metabolic pathways are 
regulated to achieve a balance between ATP production and biomass production.  However, this 
solution is not unique to cancer, as many phenotypes found in cancer cells also exist in normal 
proliferating cells and fast growing unicellular organisms. 
A major source of cellular energy and new cell mass is glucose.  Glucose is metabolized 
via glycolysis to pyruvate, which can be oxidatively metabolized to CO2 in the tricarboxylic acid 
(TCA) cycle to generate large amounts of ATP through the process of oxidative phosphorylation.  
Pyruvate can also be reductively metabolized to organic acids or alcohols (e.g., lactate, acetate, 
or ethanol), a process known as fermentation.  Glucose fermentation does not require oxygen, 
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but it is far less efficient in generating ATP.  Despite decreased efficiency in ATP production, 
many fast growing unicellular organisms rely primarily on glucose fermentation during 
proliferation regardless of oxygen availability.  For example, fermentative yeasts like S. 
cerevisiae (baker’s yeast), which prefer to ferment glucose to ethanol even under aerobic 
conditions, grow faster when using fermentation rather than respiration (Rolland et al 2002).  
Although S. cerevisiae depend on oxidative phosphorylation in glucose-poor environments with 
only non-fermentable carbon sources, they immediately arrest respiration and accelerate 
glycolysis if glucose becomes available (Woehrer & Roehr 1981), a phenomenon known as the 
Crabtree effect (Crabtree 1929).  Another well studied example is blood stage malaria parasites: 
they predominantly use glucose fermentation instead of oxidative phosphorylation for ATP 
production (Sherman 1998).  When fed 14C-glucose, malaria parasites do not generate a 
significant amount of 14CO2, suggesting that the majority of glucose is not oxidized in the TCA 
cycle despite high oxygen concentrations in blood; instead, a large amount of 14C-glucose is 
metabolized to 14C-lactate (Bryant et al 1964).  Blood cells infected with malaria also exhibit 
much higher glucose uptake than normal blood cells (Bryant et al 1964).  While glucose 
fermentation is a common feature of many proliferating cells, it is not required for proliferation; 
aerobic yeasts such as Y. lipolytica rely solely on respiration (Christen & Sauer 2010), and E. 
coli do not undergo fermentation under aerobic conditions, only excreting the fermentative 
product acetate when glucose uptake exceeds a maximum respiration rate (Valgepea et al 2010, 
Xu et al 1999).  Thus, evolution has devised more than one metabolic solution to support cell 
proliferation. 
Like many unicellular organisms, multicellular organisms also exhibit enhanced 
glycolysis during fast growth.  In 1924, Otto Warburg observed that cancer cells consume much 
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larger quantities of glucose than their normal counterparts and metabolize it predominantly 
through glycolysis, producing high levels of lactate even in oxygen-rich conditions (Warburg 
1956, Warburg et al 1924).  This phenomenon of aerobic glycolysis (i.e., conversion of glucose 
to lactate even in the presence of sufficient oxygen to support glucose catabolism via the TCA 
cycle with oxidative phosphorylation) is not exclusive to cancer cells.  Many non-transformed 
cells also exhibit high aerobic glycolysis during rapid proliferation.  In proliferating mouse 
fibroblasts, the rate of glucose uptake and lactate production is highest during logarithmic growth 
(Munyon & Merchant 1959).  Increased glucose uptake and lactate excretion has been observed 
in mitogen-stimulated normal human lymphocytes (Hedeskov 1968), mouse lymphocytes (Wang 
et al 1976), and rat thymocytes (Brand 1985, Hume et al 1978).  Further, no difference in lactic 
acid production was observed during optimal growth between normal and transformed chick 
embryo cell cultures (Steck et al 1968).  These studies suggest that aerobic glycolysis is a 
common phenomenon among many proliferating animal cells. 
In these rapidly dividing cells, most of the glucose is converted to lactate, and very little 
is oxidized to carbon dioxide.  This observation led Warburg to suggest that cancer cells arise 
from a defect in mitochondrial respiration that causes them to rely on enhanced glycolysis.  
However, it is now clear that respiration is not impaired in most cancer cells (Fantin et al 2006, 
Moreno-Sanchez et al 2007, Zu & Guppy 2004).  Aerobic glycolysis has been observed in a wide 
variety of tumors that originate from different cell types, but most normal cells in adult tissues 
from which cancer cells arise generally do not utilize aerobic glycolysis.  Thus, cancer cells 
revert to a metabolic phenotype that is characteristic of rapidly dividing cells, suggesting that 
aerobic glycolysis must provide advantages during proliferation. 
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Aerobic glycolysis is not selected for increased ATP production 
Glycolysis is inefficient in terms of adenosine triphosphate (ATP) production, generating 
only 2 ATP molecules per molecule of glucose, whereas complete oxidation of one glucose 
molecule by oxidative phosphorylation can generate up to a maximum of 36 ATP molecules 
(Berg et al 2007).  Despite its low efficiency in ATP yield per molecule of glucose, aerobic 
glycolysis could generate more ATP than oxidative phosphorylation by producing ATP at a 
faster rate (Pfeiffer et al 2001).  As long as glucose supply is abundant, an inefficient yet faster 
pathway for ATP production may be preferred, and one proposed advantage of aerobic 
glycolysis is faster ATP production to meet the high demands of dividing cells.  However, 
glycolysis is not the major contributor of ATP in most cells: a compilation of data for 31 cancer 
cell lines/tissues from studies that determine oxidative ATP production (by measuring O2 
consumption) and glycolytic ATP production (by measuring lactate excretion) show that the 
average percentage of ATP contribution from glycolysis is 17% (Zu & Guppy 2004).  This 
collection of data does not support the hypothesis that cancer cells exhibit aerobic glycolysis to 
generate ATP faster, since in many cancer cells the majority of ATP is generated through 
oxidative phosphorylation.  It is important to note that the glycolytic ATP contributions are 
entirely dependent on the cell context and have a wide range (0.31 – 64%) depending on 
cell/tissue type and experimental conditions (Zu & Guppy 2004).  Cells exhibit different 
metabolic phenotypes depending on the growth environment (e.g., hypoxia) and phase of the cell 
cycle.  For example, aerobic glycolysis (as measured by lactate excretion) in mitogen stimulated 
mouse lymphocytes changes throughout the cell cycle, reaching a peak in S phase (Wang et al 
1976).  Also, budding yeast S. cerevisiae display robust, periodic cycles of glycolytic and 
respiratory metabolism in nutrient-limited conditions (Tu et al 2005). 
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ATP is likely not limiting in proliferating cells.  Estimations of biosynthetic and 
maintenance energy requirements suggest that biosynthesis to produce a new cell is not the major 
consumer of ATP (Kilburn et al 1969).  In fact, the rate-limiting step in glycolysis (i.e., 
phosphofructokinase) of Ehrlich ascites tumor cells was shown to be limited by the consumption, 
not production, of ATP (Scholnick et al 1973).  Additionally, cancer cells utilize the less active 
M2 splice isoform of pyruvate kinase, which catalyzes the step in glycolysis responsible for net 
ATP synthesis (Mazurek et al 2005).  Further, PKM2-expressing cells can uncouple the 
production of ATP from the conversion of PEP to pyruvate by using an alternate pathway 
(Vander Heiden et al 2010), suggesting that glycolysis can occur in proliferating cells without 
generating ATP. 
An important challenge to understanding proliferative cell metabolism may be resolving 
how enough ATP is consumed to support the observed high rate of glycolysis (Racker 1976).  
Consumption of ATP is needed to prevent inhibition of key rate limiting steps in glycolysis by a 
high ATP to adenosine monophosphate (AMP) ratio.  In particular, the phosphofructokinase step 
of glycolysis is sensitive to the ATP/AMP ratio and controls the entry of glucose metabolites into 
the downstream steps of glycolysis (Berg et al 2007).  A recent study reports a mechanism by 
which cells increase ATP consumption in order to drive glycolytic flux (Fang et al 2010), 
supporting the notion that ATP consumption can increase glycolytic flux 
ATP may not be limiting for growth, but it is still required by proliferating cells for both 
cellular maintenance functions and biosynthetic reactions.  ATP is necessary to maintain 
homeostasis and keep cells alive; loss of intracellular ATP results in cell necrosis or apoptosis 
(Tsujimoto 1997).  Additional ATP is necessary for cell proliferation: macromolecular synthesis 
(Xn + X → Xn+1) is a thermodynamically unfavorable process that only occurs when coupled to 
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ATP hydrolysis (to provide free energy).  Elongation of DNA, RNA, and proteins requires an 
NTP (or dNTP) for every unit added (e.g., amino acid + ATP + tRNA → amimoacyl-tRNA + 
AMP + PPi), and when ATP is converted to AMP, two ATP molecules are required to regenerate 
ATP from AMP.  ATP is also needed for many reactions that generate biosynthetic precursors.  
For example, as shown in Table 1, nucleotide and lipid biosyntheses require a significant amount 
of ATP. 
It is important to remember that mitochondria are not defective in most proliferating 
cells.  They are quite active and generate the majority of ATP in many normal and cancer cells 
(Zu & Guppy 2004).  In fact, mitochondrial activity is enhanced in stimulated lymphocytes when 
compared with resting lymphocytes, and maximal activity correlates with peak DNA synthesis 
during S phase (Darzynkiewicz et al 1981).  In breast cancer cells, knockdown of p32, a protein 
overexpressed in certain cancer cells, shifts metabolism from oxidative phosphorylation to 
glycolysis but impairs tumorigenesis, suggesting that enhanced glycolysis cannot support tumor 
growth without adequate oxidative phosphorylation (Fogal et al 2011).  Further, cancer cells are 
susceptible to mitochondrial inhibitors, and mitochondria are emerging as chemotherapeutic 
targets (Fantin & Leder 2006, Neuzil et al 2007).  It has been suggested that under conditions of 
hypoxia or fluctuating oxygen availability in which mitochondria cannot generate enough ATP, 
aerobic glycolysis may give tumors a growth advantage (Postovit et al 2002, Pouyssegur et al 
2006).  However, oxygen is not limiting for electron transport until levels are extremely low:  
even at an O2 concentration of 25 µM, electron transport is reduced only by 33% (Chandel et al 
1996).   
 ATP generated from aerobic glycolysis is undoubtedly important for cellular function and 
plays an important role in biosynthesis for at least some proliferating cells.  However, as we 
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describe below, the importance of aerobic glycolysis for proliferating cells likely extends beyond 
rapid ATP production to also allow nutrient assimilation into biosynthetic precursors and 
facilitate biomass accumulation. 
 
A major function of aerobic glycolysis is to support macromolecular synthesis  
Generating new daughter cells requires the replication of all cellular contents, including 
DNA, RNA, proteins, and lipids.  Glucose can provide the precursors for the chemical 
constituents (e.g., nucleotides, amino acids, and lipids) that are used to build macromolecules 
essential for cell division.  Therefore, a main function of upregulated glycolysis in proliferating 
cells may be to maintain levels of glycolytic intermediates needed to support biosynthesis (Hume 
& Weidemann 1979, Vander Heiden et al 2009).  Understanding the role of glycolysis during 
proliferation requires a thorough analysis of central carbon metabolism and its myriad 
connections to macromolecular biosynthesis.  Figure 1 shows the connections between glycolysis 
and the generation of many biosynthetic precursors. 
DNA and RNA, which are made of nucleotides, account for a significant portion of cell 
mass.  DNA and RNA make up 24-28% of the total dry weight in E. coli (Lewin 1997, Neidhardt 
& Umbarger 1996).  This is mostly due to ribosomes, which make up approximately 30% of the 
mass of an E. coli cell (Lewin 1997), and this percentage is likely similar in eukaryotic cells, as 
ribosome structure and function are highly conserved across all organisms (Nakamoto 2009, 
Wilson & Noller 1998).  By mass, the ribosome is composed of approximately 70% RNA in 
prokaryotes and 56-62% in eukaryotes (Morgan et al 2000).   Thus, approximately 80% of the 
RNA synthesis in proliferating cells goes to generating ribosomes (Ecker & Kokaisl 1969) and 
represents the major site of incorporation for newly synthesized  nucleotides.   
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Each purine nucleotide (ATP, GTP, dATP, and dGTP) synthesized by the cell requires 
the assimilation of 10 carbons from the extracellular environment (Figure 1 and Table 2).  Half 
of the purine nucleotide carbon is derived from 5-phosphoribosyl-α-pyrophosphate (PRPP), an 
activated version of ribose-5-phosphate, which ultimately is derived from carbohydrate nutrients, 
with glucose being the major carbohydrate available to most animal cells.  The activity of PRPP 
synthetase, an enzyme that converts ribose-5-phosphate to PRPP, increases 2-10 fold in 
lymphocytes following mitogen stimulation (Chambers et al 1974), highlighting the importance 
of increased PRPP generation for nucleotide biosynthesis during cell growth.  Two carbons in 
purines come from glycine, which can come from the extracellular environment or be 
synthesized from the glycolytic intermediate 3-phosphoglycerate.  Two molecules of N10-formyl-
tetrahydrofolate (N10-formyl-THF), one of many folates that can accept or donate one-carbon 
units, provide 2 carbons in purine synthesis.  Folates acquire most of their carbon units from 
either serine or glycine, both of which can be derived from 3-phosphoglycerate (folates can also 
obtain one carbon units from formate).  Thus, through glycolysis, glucose is a significant carbon 
source for purine nucleotides, providing a minimum of 5 carbons and up to 9 carbons.  Purine 
nucleotides can also be synthesized by salvage pathways (e.g., guanine + PRPP → GMP + PPi), 
but this requires an exogenous source of the purine base to allow a net increase in cell mass.  
Generating nucleotides via the salvage pathway still requires PRPP that is largely derived from 
glycolysis, but the salvage pathway considerably decreases the amount of ATP required.  
Inhibitors of de novo purine biosynthesis inhibit lymphocyte growth, suggesting purine salvage 
pathways are insufficient to support nucleotide synthesis (Hovi et al 1976).  In addition to 
serving as building blocks of nucleic acids, purines are necessary for cofactor biosynthesis, as 
adenine is present in FAD(H), NAD(H), NADP(H), and coenzyme A (CoA).   
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Next, consider the biosynthetic precursors that provide the 9 carbons in pyrimidine 
nucleotides (CTP, UTP, dCTP, and dTTP; see Figure 1 and Table 2). Glycolysis is also a major 
source of carbons for biosynthesis of these nucleotides, as the majority (5 out of 9) of carbons 
comes from PRPP.  Three of the remaining carbons in pyrimidine nucleotides come from 
aspartate, which can be acquired directly from the environment or generated from the TCA cycle 
intermediate oxaloacetate.  Carbons in oxaloacetate can be derived from glucose or provided by 
glutamine, as will be discussed in later sections.  Unlike other pyrimidines, thymidine contains 
one additional carbon, which comes from folates.  The folate species 5,10-methylene-
tetrahydrofolate provides this carbon to convert dUMP to dTMP, which is phosphorylated to 
dTTP for incorporation into DNA.  This folate-dependent production of dTMP is the target of 
current chemotherapeutic agents such as methotrexate, 5-fluroruracil, and pemetrexed, 
highlighting the importance of these biosynthetic reactions for proliferating cells.    
Experimental evidence supports the notion that glycolysis is necessary for DNA 
synthesis, especially during S phase of the cell cycle.  In mitogen-stimulated mouse 
lymphocytes, the exponential increase in lactate production for the first 50 hours and the 
subsequent decrease exactly parallels 3H-thymidine incorporation into DNA (Wang et al 1976), 
suggesting a link between aerobic glycolysis and DNA synthesis.  Consistent with this 
observation, 3H-thymidine incorporation into DNA increases with increasing glucose 
concentration in mitogen stimulated rat thymocytes (Hume et al 1978).  In stimulated human 
peripheral lymphocytes, glycolytic enzyme activities, lactate production, and DNA synthesis 
reach maximum levels in S phase of the cell cycle (Marjanovic et al 1988).  Further, studies of 
cell proliferation in the absence of glucose have demonstrated that HeLa cells, mouse L cells, 
early passage human fibroblasts, and primary chicken embryo fibroblasts can all grow 
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indefinitely at near maximal growth rates without glucose as long as they are supplemented with 
glutamine and uridine (Wice et al 1981).  Uridine (uracil attached to a ribose ring) can be 
converted to PRPP (uridine + ATP → UMP + ADP; UMP + PPi → PRPP + uracil) to support 
nucleotide biosynthesis.  While not directly examined in these studies, additional nutrients (such 
as amino acids and vitamins) present in mammalian tissue culture media used for these 
experiments are also likely required to support proliferation in the absence of glucose.  A more 
recent study demonstrated cells could grow in size using the amino acid glutamine as the only 
major carbon source, but were unable to proliferate unless a metabolite capable of entering 
glycolysis was available (Wellen et al 2010), presumably to support nucleic acid synthesis.  
These findings support the importance of glycolysis in providing nucleotide precursors under 
physiological cell growth conditions for animal cells where glucose is the major nutrient 
available. 
In addition to supporting nucleotide biosynthesis, glycolysis is also a major source of 
carbon for lipid precursors.  Lipid-containing cell membranes comprise ~10% of the mass of an 
E. coli cell (Lewin 1997, Neidhardt & Umbarger 1996), and this percentage is likely larger for 
eukaryotic cells, which contain complex internal membrane systems in addition to the plasma 
membrane (Alberts et al 2002).  In Ehrlich ascites tumor cells, > 93% of triacylglycerol fatty 
acids are synthesized de novo (Ookhtens et al 1984) and the synthesis of most fatty acids from 
external nutrients is a common feature shared by most proliferating cells (Menendez & Lupu 
2007).  Further, increased activity of lipogenesis enzymes are implicated in tumor growth:  fatty 
acid synthetase (FASN) is overexpressed in cancer cells (Kuhajda 2000), and inhibition of FASN 
activity has been shown to kill cancer cells and hinder the growth of tumors in xenograft models 
(Lupu & Menendez 2006).  Tumor growth can also be impaired by inhibition of ATP citrate 
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lyase (ACL), the enzyme that cleaves citrate to generate acetyl-CoA for fatty acid synthesis 
(Hatzivassiliou et al 2005).     
The glycolytic intermediate dihydroxyacetone phosphate (DHAP) is the precursor to 
glycerol-3-phosphate, which is crucial for the biosynthesis of phospholipids and triacylglycerols 
that serve as major structural lipids in cell membranes.  Elevated levels of glycerol and glycerol-
3-phosphate have been reported in human peripheral lymphocytes after mitogen stimulation 
(Roos & Loos 1970), and elevated levels of choline phospholipids have been found in brain 
tumors (Preul et al 1996) and breast cancer tumors (Katz-Brull et al 2002).  DHAP is also the 
precursor for lipids such as cardiolipin, an important component of mitochondrial membranes.  
The glycolytic intermediate 3-phosphoglycerate is the precursor of sphingolipids, another major 
class of lipids in cells.  In addition to being important membrane lipids, sphingolipids play a role 
in signaling, as these lipids are implicated in cell growth, differentiation, senescence, apoptosis, 
and cancer (Futerman & Hannun 2004, Ogretmen & Hannun 2004).   
A large proportion of the cell membrane carbon is derived from acetyl-coA.  Acetyl-coA 
provides the carbon for synthesis of fatty acyl chain components of the various lipid classes and 
also provides the carbon to synthesize mevalonate, a precursor for cholesterol and related 
molecules (Figure 1).   Glucose can be a major source of acetyl-coA production, but acetyl-coA 
derived from glucose is not a direct product of glycolysis.  Oxidative decarboxylation of 
pyruvate to acetyl-CoA occurs in mitochondria, but mitochondrial acetyl-coA is not accessible 
for lipid biosynthesis in the cytosol.  Instead, the acetyl-coA enters the TCA cycle where it can 
be exported to the cytosol as citrate, from which acetyl-coA can be recovered via the action of 
ATP citrate lyase.  The ability to generate cytosolic acetyl-coA is critical for cell proliferation 
(Hatzivassiliou et al 2005). 
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Much of the remaining mass of the cell is protein, which makes up 49-55% of dry cell 
mass in E. coli (Lewin 1997, Neidhardt & Umbarger 1996) and a similar percentage in 
mammalian cells (Alberts et al 2002).  This high protein content imposes a large amino acid 
requirement on proliferating cells.  Amino acid availability provides the dominant input for the 
cell growth signal transduction machinery.  The target of rapamycin (TOR) protein (refered to as 
mTOR in mammalian cells) is a serine/threonine kinase that coordinates activation of the cell 
growth machinery with amino acid availability, and in metazoans also with the presence of 
growth signals and other metabolic conditions (Sengupta et al 2010, Wullschleger et al 2006).  
Glycolytic intermediates are direct precursors for the biosynthesis of some amino acids (Figure 
1), and Table 1 shows the carbon precursors for nonessential amino acids.  The carbons of four 
nonessential amino acids are derived from glycolytic intermediates: 3-phosphoglycerate provides 
the carbons for cysteine, glycine, and serine; and pyruvate provides the carbons for alanine.  As 
mentioned previously, serine and glycine are involved in folate metabolism as carbon donors for 
many biosynthetic reactions, and serine is added directly to glycerol as the head group in 
phosphatidylserine biosynthesis.   
Close examination of biosynthetic requirements and evidence linking glycolytic activity 
to macromolecular synthesis suggest that the major function of enhanced glycolysis in 
proliferating cells is to maintain constant levels of glycolytic intermediates as macromolecular 
precursors.  This clearly illustrates that increased glycolysis in cancer cells, and other 
proliferating cells, provides a selective advantage for growth beyond rapid ATP generation. 
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Why do proliferating cells excrete so much lactate?  
In rapidly dividing cells, much of the glucose is converted to lactate.  If glycolysis is 
increased to supply carbon building blocks for biomass production, why is so much carbon 
excreted as lactate?  The rate of utilization of glycolytic intermediates for biosynthesis of 
macromolecules accounts for less than 10% of the glycolytic rate:  in stimulated rat thymocytes, 
the percentage of glucose uptake accounted for by macromolecule synthesis (DNA, RNA, 
protein, and lipids) is ~7% (Hume et al 1978), and in human glioma cells, lactate and alanine 
production accounts for ~93% of glucose uptake, leaving ≤ 7% for macromolecule synthesis 
(DeBerardinis et al 2007).   
Having a seemingly wasteful, high glycolytic flux to lactate and a low flux to 
biosynthetic precursors may contribute to the regulation of biomass production, allowing cells to 
ramp up biosynthesis only during cell proliferation.  A low flux pathway (biosynthesis) 
branching from a high flux pathway (glycolysis) would be highly sensitive to a decrease in the 
high flux pathway (Newsholme et al 1985b): while biosynthesis can occur during periods of high 
glycolytic flux, it would quickly halt when glycolytic flux is low.  This strategy allows for 
maximum biosynthesis of macromolecules from glycolytic intermediates only when precursor 
concentrations are maintained at adequate levels.  Indeed, glycolytic intermediates are 
maintained at high levels in the G1 phase of the cell cycle and at especially high levels in tumor 
cells (Eigenbrodt et al 1992), and this is supported by increased glycolytic flux with a high rate 
of lactate production.  Additionally, a rapid accumulation of PRPP is observed in thymocytes 
after mitogenic stimulation (Hovi et al 1975), and this may be directly caused by increased 
intracellular concentrations of glucose-6-phosphate (Culvenor & Weidemann 1976) to support 
nucleotide biosynthesis.  Thus, during cell growth, glycolytic flux may be enhanced to allow for 
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fast cell growth by maintaining the pool sizes of glycolytic intermediates as they are depleted for 
anabolic reactions.   
Pyruvate, the end product of glycolysis, has three major fates in mammalian cells:  1) 
conversion to lactate via lactate dehydrogenase (LDH); 2) conversion to alanine via alanine 
aminotransferase (ALT) with the concomitant conversion of glutamate to α-ketoglutarate; or 3) 
conversion to acetyl-CoA in the mitochondria via the pyruvate dehydrogenase (PDH) complex to 
enter the TCA cycle (Figure 1).  The high glycolytic flux in proliferating cells may be 
significantly greater than the maximum PDH activity (Curi et al 1988), leaving higher 
concentrations of cytosolic pyruvate for LDH and alanine aminotransferase.  Though less well 
appreciated than lactate production, some cancer cells also excrete large amounts of alanine 
(DeBerardinis et al 2007), suggesting that the excretion of both molecules is a means to eliminate 
excess pyruvate.  Consistent with this, pyruvate levels often mirror lactate levels in cells 
(Christofk et al 2008a). 
Lactate generation has an important role in glycolysis:  conversion of pyruvate to lactate 
via LDH regenerates NAD+.  For glycolysis to continue, the NAD+/NADH redox balance must 
be maintained; NAD+ regeneration is necessary for continued flux through glycolysis, as NAD+ 
is required for conversion of glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate.  
Maintenance of the cellular redox state is also important for regulating gene expression 
(Ladurner 2006).  For example, the circadian clock is regulated by NAD(P) cofactors: the 
reduced forms (NADH and NADPH) activate transcription factors that control gene expression 
as a function of the light-dark cycle, and the oxidized forms (NAD+ and NADP+) inhibit DNA 
binding (Rutter et al 2001).  Further, NADH levels regulate the transcriptional regulator C-
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terminal binding protein, which is involved in cell growth, differentiation and transformation 
(Zhang et al 2002). 
The mitochondrial electron transport chain can accept electrons from NADH to 
regenerate NAD+, but the electrons must be transported into the mitochondrial matrix by other 
metabolites (e.g., malate) via cytoplasmic shuttle systems (e.g., malate-aspartate shuttle).  The 
malate-aspartate shuttle involves up to 6 separate reactions and is kinetically much slower than 
pyruvate to lactate conversion.  LDH is an extremely efficient enzyme over a range of substrate 
conditions when the enzyme is abundant (Wuntch et al 1970).   Many proliferating cells express 
LDH at high levels, and a high NADH/NAD+ ratio resulting from elevated glycolysis may drive 
the production of lactate.  NAD+ is also necessary for nucleotide and amino acid biosynthesis 
(see Figure 1 and Table 1), suggesting that lactate production may allow faster glucose flux 
through glycolysis along with faster incorporation of glucose metabolites into biomass by 
efficiently regenerating NAD+.  For most unicellular organisms, rapid proliferation has a 
selective advantage to outcompete other cells when nutrients are abundant.  In animals, nutrients 
are rarely limiting for individual cells, but the ability to proliferate quickly (e.g., to mount an 
immune response or close a wound) provides a strong selection for rapid division.  Viewed from 
this perspective, faster growth involving lactate loss is more important than the efficiency of 
carbon utilization for many cells (Vander Heiden et al 2009). 
Lactate generation may have secondary benefits for tumors cells.  Excreting high levels 
of lactate may support their survival, growth, and invasion by conditioning the tumor 
microenvironment (Koukourakis et al 2006), promoting tumor invasion (Gillies & Gatenby 
2007, Swietach et al 2007), and suppressing anticancer T-cell immune response (Fischer et al 
2007).  While these sequelae could contribute to dysregulated tumor growth, these advantages 
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that arise from high lactate excretion are likely not the selective pressures responsible for aerobic 
glycolysis.  The biosynthetic benefits of aerobic glycolysis (i.e., obtaining much of the carbons 
needed to replicate the entire contents of a cell) outweigh the invasive benefits provided by 
lactate.  It is more likely that cells produce lactate to regenerate NAD+ for continued glycolytic 
flux.  Further, many normal proliferating cells utilize aerobic glycolysis but do not derive benefit 
from lactate.  Thus, it is unlikely that aerobic glycolysis is selected for in cancer cells because of 
high lactate excretion. 
 
How is enough NADPH generated to support cell proliferation? 
NADPH (reduced nicotinamide adenine dinucleotide phosphate) is a cofactor important 
for cell proliferation.  As shown in Figure 1 and Table 1, NADPH is necessary as a reducing 
agent for nucleotide, amino acid, and lipid biosynthesis.  Lipid synthesis demands a great deal of 
NADPH. Generating palmitoyl-CoA, a fatty acyl-CoA, claims 14 molecules of NADPH (Vander 
Heiden et al 2009), and sphingolipid, phospholipid, and triacylglycerol biosynthesis employs 
one, two, and three molecules of fatty acyl-CoA’s, respectively, imposing a large NADPH 
requirement.   Cholesterol biosynthesis involves 26 molecules of NADPH.  In fact, it has been 
proposed that NADPH production may be rate limiting for cell proliferation (Vander Heiden et al 
2009).  The major source of NADPH during cell growth is widely assumed to be the oxidative 
reactions of the pentose phosphate pathway (Feron 2009, Lehninger et al 1993).  However, 
labeling experiments using 1,2-13C-labeled glucose in multiple cancer cell types have suggested 
that the pentose phosphate pathway cannot account for the NADPH requirements of proliferation 
in at least some cancer cells (Boros et al 1998, Boros et al 2000).  Studies also suggest that the 
pentose phosphate pathway is a minor source for NADPH production in proliferating E. coli 
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(Csonka & Fraenkel 1977).  Further, many patients deficient in glucose-6-phosphate 
dehydrogenase (one of the enzymes in the oxidative pentose phosphate shunt responsible for 
NADPH production) are asymptomatic, and there is no evidence they have decreased cancer risk 
(Cocco 1987).  
It has been shown that metabolism of glutamine through malic enzyme (malate 
dehydrogenase (decarboxylating)) can be a significant source of NADPH in human glioma cells 
(DeBerardinis et al 2007).  Each molecule of glutamine-derived lactate can generate up to one 
molecule of NADPH if glutamine is oxidatively metabolized to malate, which is converted to 
pyruvate via malic enzyme.  Pyruvate can then re-enter the TCA cycle or be excreted as lactate.  
Estimating NADPH production from malic enzyme via isotopically labeled lactate produced 
from labeled glutamine is challenging, as cyclical flux between pyruvate and TCA cycle 
metabolites (e.g., pyruvate → citrate → malate → pyruvate) do not allow unique isotope-
labeling detection.  Nonetheless, more than half of the glutamine taken up by glioblastoma cells 
is excreted as lactate, suggesting this pathway may be a significant source of NADPH production 
for some cancer cells (DeBerardinis et al 2007).  However, not all cancers exhibit high glutamine 
uptake.  Glutamine uptake and metabolism is regulated by the oncogene MYC, and MYC-
transformed cells become addicted to glutamine through increased expression of glutamine 
transporters and glutamine catabolic enzymes (Dang 2010, Gao et al 2009, Wise et al 2008).  
Thus, other means of generating NADPH must exist for cancer cells less dependent on 
glutamine. 
Cytosolic isocitrate dehydrogenase (IDH1) generates NADPH when converting isocitrate 
to α-ketoglutarate.  IDH1 may be a significant source of NAPDH for some cancer cells 
(Thompson 2009), and siRNA knockdown of IDH1 is toxic to a cancer cell line that expresses 
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wildtype IDH1 (Ward et al 2010).  Cancer cells that rely on the reductive metabolism of 
glutamine also require IDH1; however, in these cells net flux appears to be production of 
isocitrate from glutamine, leading to NADPH consumption, not production.  Furthermore, 
mutations in IDH1 are found in human cancers that result in a neomorphic activity to consume 
NADPH during conversion of α-ketoglutarate to 2-hydroxyglutarate (Dang et al 2009).  IDH1 
mutations always involve only one allele, but expression of the mutant enzyme has been reported 
to act as a dominant inhibitor of normal IDH1 provided by the remaining allele (Zhao et al 
2009).  Additional work is required to determine which cancer cells rely on NADPH production 
via IDH1, malic enzyme, and/or the oxidative pentose phosphate pathway.  Furthermore, it 
remains possible that other sites of NAPDH production are important for proliferation in some 
cells. 
 
Glutamine is also important for anaplerosis and ATP production 
In addition to serving as a source of NADPH production, glutamine contributes to 
bioenergetics, macromolecular synthesis, and glutathione production for protection against 
oxidative stress (DeBerardinis & Cheng 2010).  In nonproliferating cells, the main role of the 
TCA cycle is to maximize ATP production, oxidizing substrates completely to CO2.  In 
proliferating cells, however, the TCA cycle serves as an important source of biosynthetic 
precursors (DeBerardinis et al 2008) in addition to providing ATP.  Mitochondrial citrate is used 
for lipid biosynthesis while oxaloacetate and α-ketoglutarate are used to generate four 
nonessential amino acids (aspartate, asparagine, glutamate, and proline; see Figure 1).  The 
efflux of these TCA cycle intermediates for biosynthesis is called cataplerosis.  In order for 
cataplerosis to be sustainable, the TCA cycle intermediates must be replenished, and this process 
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is called anaplerosis.  Anaplerosis of TCA cycle intermediates can be supported by pyruvate and 
various amino acids.  Pyruvate is converted to oxaloacetate by pyruvate carboxylase in the 
mitochondrial matrix.  Amino acids enter the TCA cycle via pyruvate, acetyl-CoA, acetoacetyl-
CoA, α-ketoglutarate, succinyl-CoA, fumarate, and oxaloacetate (Owen et al 2002, Voet & Voet 
2004).  Glutamine, the most abundant amino acid in human plasma (Stein & Moore 1954), is a 
major contributor to anaplerotic flux.  Labeling studies show that glutamine significantly 
contributes to anaplerosis in both rat and human glioma cells (DeBerardinis et al 2007, Portais et 
al 1996).  Glutamine depletion induces MYC-dependent apoptosis of normal human fibroblasts, 
but apoptosis can be rescued by addition of pyruvate or oxaloacetate (Yuneva et al 2007).  
Pyruvate and oxaloacetate do not contain any nitrogen, suggesting that cell death induced by 
glutamine starvation is due to lack of glutamine-derived carbons.  Glutamine anaplerotic flux 
may also be important for mitochondrial production of NADH and FADH, as NADH/NAD+ and 
FADH/FAD+ ratios are important for mitochondrial integrity and function (Jonas et al 2004). 
In proliferating cells, glutamine carbons are converted to amino acids, TCA cycle 
intermediates, lactate, and CO2 (Hanson & Parsons 1977, Lanks 1987, Newsholme et al 1985a, 
Watford et al 1979).  Figure 2 provides an overall schematic for contributions of glucose and 
glutamine to biomass, lactate, and CO2.  Due to similarities with glycolysis in lactate production 
and partial oxidation to CO2, this metabolism of glutamine is referred to as glutaminolysis 
(McKeehan 1982).  By contributing to anaplerotic flux, glutamine provides carbons for TCA 
cycle intermediates that serve as precursors of many nonessential amino acids (Table 1).  
Glutamine is also an important source of carbon for fatty acids, as acetyl-CoA can also be 
derived from glutamine in addition to glucose (DeBerardinis et al 2007, Yoo et al 2004).  
Further, glutamine is a nitrogen source for nucleotides (Table 2), amino acids, and hexosamines 
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(amino sugars such as glucosamine, a precursor to glycosylated proteins and lipids).  Glutamine 
can be converted to glutamate, which serves as a nitrogen donor to amino acids through 
transamination reactions.  Glutamate is also important for folate metabolism: glutamates are 
added to folates to increase cell retention and regulate enzyme activity, and antifolates can stop 
cell growth by inhibiting glutamate addition to folates (Kwon et al 2008). 
Glutamine carbons also contribute to fatty acid biosynthesis.  In human glioma cells, 5% 
of 14C-glutamine-derived carbon is incorporated into fatty acids (Wise et al 2008).  This 
percentage may be higher under certain conditions, as reductive metabolism of glutamine can 
occur and lead to significant incorporation of glutamine carbon into acetyl-coA (Yoo et al 2008).  
Reductive glutamine metabolism is favored under low oxygen conditions and can be a major 
contributor of carbon to lipid synthesis.   
Glutaminolysis has the capacity to generate more ATP than glycolysis.  While ATP 
generation from glucose has been emphasized, glutamine’s contribution to ATP production in 
proliferating cells may have been underappreciated.  Glutamine is well known for its role in 
anaplerosis, protein biosynthesis, and nucleotide biosynthesis (as an amino group donor).  
However, glutamine may also be an important respiratory fuel for proliferating cells, 
significantly contributing to cellular ATP production.  Isolated rat intestinal cells selectively 
uptake large amounts of glutamine from blood even in the presence of 10 to 15 mM glucose, 
amounts higher than physiological concentrations.  The majority of 14C-glutamine carbons (57%) 
were released back into the blood as 14CO2 in this experiment, while only 14% appeared in tissue 
(Windmueller & Spaeth 1974).  In mouse L-M strain fibroblasts grown in medium containing 11 
mM glucose, 55% of 14C-glutamine uptake is converted to 14CO2, contributing up to 35% of the 
ATP requirement for these cells (Stoner & Merchant 1972).  Similarly, glutamine provides 
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approximately 30% of the cellular ATP requirement in human diploid fibroblasts cultured in 
minimum essential medium (MEM) containing ≥ 5.5 mM glucose (Zielke et al 1978).  In 
cultured HeLa cells, more than half of the ATP requirement (determined by comparing 14CO2 
production from 14C-glutamine to 14CO2 and 14C-lactate production from 14C-glucose) comes 
from glutamine even when a high concentration (10 mM) of glucose is present (Reitzer et al 
1979).  Thus, glutamine is a critical nutrient that serves myriad functions to support proliferative 
cell metabolism. 
 
Metabolic reprogramming for proliferation  
In metazoans, normal cells grow and divide only when signal transduction pathways are 
activated by growth factors.  These signaling pathways control gene expression and cell 
physiology, leading to cell cycle progression.  Additionally, they impact metabolism to allow for 
cell growth.  The metabolic changes induced by cell growth signals are largely conserved 
between normal and cancer cells; however, cancer cells activate signaling pathways in the 
absence of normal extracellular cues, promoting a metabolic phenotype that allows inappropriate 
cell proliferation.  A major regulator of glucose metabolism is the phosphoinositide 3-kinase 
(PI3K) signaling pathway.  PI3K signaling through the protein kinase Akt can increase uptake of 
glucose by increasing expression of the glucose transporter Glut1 (Barthel et al 1999, Frauwirth 
et al 2002, Vander Heiden et al 2001), and maintaining its levels on the cell surface by 
preventing internalization (Wieman et al 2007).  Akt activation enhances flux through glycolysis 
(Elstrom et al 2004) in part by maintaining hexokinase association with mitochondria (Gottlob et 
al 2001) and activating phosphofructokinase 2 (PFK-2) through phosphorylation (Deprez et al 
1997).  In normal cells, the PI3K pathway is tightly controlled to increase glucose uptake and 
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metabolism in response to growth signals (Cantley 2002).  However, in cancer cells, various 
mutations activate PI3K in the absence of growth signals, suggesting that inappropriate 
activation of this pathway may be a major driver of aerobic glycolysis in cancer cells 
(DeBerardinis et al 2008). 
Rapidly proliferating cells require close proximity to blood vessels for access to oxygen 
and nutrients.  As tumors grow, cells may encounter hypoxic conditions leading to induction of 
the hypoxia inducible factor 1 (HIF-1) transcription factor.  HIF-1 increases the expression of 
vascular endothelial growth factor (VEGF) to facilitate the growth of new blood vessels.  HIF-1 
also increases the transcription of glucose transporters, many glycolytic enzymes, and lactate 
dehydrogenase A (O'Rourke et al 1996, Semenza et al 1994).   HIF-1 is a heterodimer composed 
of HIF-1α and HIF-1β (ARNT) subunits, and the biological activity of HIF-1 is determined by 
presence of the HIF-1α subunit, whose stability is regulated by oxygen levels (Kaelin & Ratcliffe 
2008).  During periods of fast growth and rapid biomass synthesis, such as embryogenesis and 
tumorigenesis, local hypoxic conditions may arise stimulating HIF-1 to enhance glycolytic gene 
expression.  HIF-1 is required for embryogenesis, as mice homozygous for a loss-of-function 
mutation in HIF-1α or HIF-1β die at midgestation (Iyer et al 1998, Maltepe et al 1997).  Loss of 
HIF-1α in tumor cells also dramatically slows their growth when injected into nude mice (Jiang 
et al 1997, Maxwell et al 1997, Ryan et al 1998).  Even under normoxic conditions, HIF-1α can 
be induced by the glycolytic metabolites pyruvate and lactate (McFate et al 2008), mTOR 
activation, NAD+ levels, reactive oxygen species, nitric oxide, many TCA cycle metabolites 
(reviewed in (Semenza 2010b)), and oncogene gain of function or tumor suppressor gene loss of 
function (reviewed in (Semenza 2010a)). 
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Activation of the PI3K pathway appears to be an important way to increase HIF-1 
transcription in cancer (DeBerardinis et al 2008, Majumder & Sellers 2005).  In addition to 
increasing the expression of glycolytic enzymes, increased HIF-1 activity promotes aerobic 
glycolysis by upregulating the expression of pyruvate dehydrogenase kinase (PDK).  HIF-1 
induced PDK activity inhibits PDH, which converts pyruvate to acetyl-CoA (Kim et al 2006, 
Papandreou et al 2006).  Inhibition of PDH activity decreases pyruvate flux into the TCA cycle, 
promoting pyruvate conversion to lactate (i.e., aerobic glycolysis).  Thus, activation of HIF 
resulting from hypoxia, PI3K activation or other mechanisms can promote glucose metabolism 
by aerobic glycolysis. 
In addition to promoting glutamine metabolism as discussed above, MYC promotes 
transcription of glucose transporters and glycolytic enzymes (Ahuja et al 2010, Osthus et al 
2000).  MYC regulates the expression of LDH-A (Shim et al 1997), and MYC-dependent tumors 
cannot proliferate when LDH-A expression is knocked down (Le et al 2010).  Further, MYC 
regulates enzymes in the nucleotide biosynthesis pathway, including thymidylate synthase, 
inosine monophosphate dehydrogenase 1 and 2, and phosphoribosyl pyrophosphate synthetase 2 
(Tong et al 2009b).  Additional transcription factors related to MYC, ChREBP and MondoA, 
control glycolytic enzyme expression and can promote anabolic metabolism in some contexts 
(Sloan & Ayer 2010, Tong et al 2009a).  RAS, another oncogene widely implicated in human 
cancer, also promotes glucose metabolism by enhancing glucose uptake (Yun et al 2009).  
Mutation of p53 is another common genetic event in human cancer, and the p53 protein prevents 
tumor growth by suppressing metabolic pathways conducive to proliferation of stressed or 
damaged cells.  p53 promotes mitochondrial respiration while inhibiting glycolysis by repressing 
glucose transporters, inhibiting the glycolytic enzyme phosphoglycerate mutase, and decreasing 
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the activity of PFK-1 through TIGAR (Cheung & Vousden 2010, Levine & Puzio-Kuter 2010).  
Thus, p53 loss of function in cancer can promote glycolysis, and signaling networks that regulate 
metabolism contribute to enhanced glycolysis observed in proliferating cells. 
 
Upstream regulation of glycolysis 
Glucose import into mammalian cells is facilitated primarily by five transmembrane 
transporters, GLUT1-5.  While GLUT2, GLUT4, and GLUT5 are only found in specific tissues, 
GLUT1 and GLUT3 are expressed in nearly all mammalian cells and have the lowest KM value 
(1 mM), allowing them to transport glucose into the cell at a nearly constant rate from serum 
where glucose concentration ranges from 4 mM to 8 mM.  Tumor cells frequently overexpress 
GLUT1 and GLUT3 and have an increased capacity for glucose uptake (Au et al 1997, Suzuki et 
al 1999, Yamamoto et al 1990, Younes et al 1996).  Suppression of GLUT1 expression in a 
human gastric cancer cell line can decrease the number of cells in S phase and inhibit tumor 
growth (Noguchi et al 2000).   
Once in the cell, glucose must be converted to glucose-6-phosphate by hexokinase to 
prevent its transport out of the cell and to prime it for metabolism in subsequent reactions (Berg 
et al 2007).  There are four known mammalian hexokinase isoforms (HK I-IV), and HK I is 
expressed in most normal cells and at particularly high levels in brain tissue (Wilson 2003).  HK 
II expression is more limited and is normally found mainly in skeletal muscle and adipose tissue.  
However, cancer cells frequently overexpress HK II (Mathupala et al 2006), and at least some 
glioblastoma cells are specifically dependent on HK II over other isoforms of the enzyme (Wolf 
et al 2011).  Both HK I and HK II are associated with the voltage dependent anion channel 
(VDAC) on the cytosolic side of the outer mitochondrial membrane.  This VDAC-hexokinase 
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association may inhibit mitochondria-induced apoptosis (Majewski et al 2004) and give 
hexokinase preferential access to mitochondria-generated ATP (Arora & Pedersen 1988).  
Preference for mitochondria-bound HK II in cancer cells remains unclear. 
While hexokinase traps glucose inside the cell, PFK-1 controls its commitment to 
glycolysis and is therefore highly regulated.  PFK-1, which irreversibly converts fructose-6-
phosphate to fructose-1,6-bisphosphate (FBP), is overexpressed in various human cancer cell 
lines (Vora et al 1985).  PFK-1 is allosterically inhibited by high levels of ATP (Berg et al 2007), 
and relieving this ATP inhibition is an important means to increase glucose metabolism in 
proliferating cells (Fang et al 2010, Israelsen & Vander Heiden 2010, Scholnick et al 1973).  
PFK-1 inhibition by ATP is diminished by fructose-2,6-bisphosphate, a metabolite synthesized 
from fructose-6-phosphate by PFK-2.  Regulation of PFK-2 expression or activity has been 
proposed as an important way to couple growth signals with regulation of glucose metabolism in 
proliferating cells (Christofk et al 2008a, Marsin et al 2000, Telang et al 2006).  In human 
tissues, PFK-1 subunit composition, a complex mixture of homotetramers or heterotetramers 
composed of up to three different subunits, can vary depending on tissue type.  Each subunit (C, 
L, M) differs in sensitivity to allosteric effectors; thus, the kinetic and regulatory properties of 
PFK-1 are determined by subunit composition (Dunaway et al 1988).  PFK subunits 
overexpressed in rat thyroid carcinomas and human gliomas are less sensitive to the allosteric 
inhibitors ATP and citrate (Meldolesi et al 1976, Oskam et al 1985, Staal et al 1987).  In addition 
to controlling glucose commitment to glycolysis, PFK-1 may regulate the amounts of glucose-6-
phosphate available for nucleotide biosynthesis. 
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Pyruvate kinase influences the fate of glucose 
Pyruvate kinase (PK) catalyzes the final irreversible step in glycolysis, generating 
pyruvate and ATP.  PK serves as a critical point in controlling the levels of glycolytic 
intermediates for biosynthesis and the availability of pyruvate for mitochondrial ATP production. 
When the cell energy charge (ATP/AMP ratio) is high, ATP inhibits PK.  PK is activated by 
FBP, the product of the glycolytic rate-controlling enzyme PFK-1.  Alanine, which can be 
synthesized from the PK product pyruvate, is an allosteric inhibitor of PK.  
Four PK isoforms with different kinetic properties exist in mammals (L, R, M1 and M2).  
The L and R isoforms are expressed in the liver and red blood cells, respectively.  The M1 
isoform is found in most adult tissues while the M2 isoform is found in rapidly proliferating fetal 
tissues.  L, R, and M2 isoforms are regulated by FBP, ATP, and phosphorylation, but the M1 
isoform is largely unregulated (Jurica et al 1998).  The M2 isoform can also be inhibited as a 
consequence of tyrosine kinase signaling in tumor cells (Christofk et al 2008b).  Many cancer 
cells exclusively express the M2 isoform of PK (Mazurek et al 2005), and PKM2 expression is 
important for tumor growth (Christofk et al 2008a).  PKM2 is less active than PKM1 both in 
vitro and in cells (Vander Heiden et al 2010), and inactivation of PKM2 appears to be mediated 
by phospho-tyrosine catalyzed release of FBP from the enzyme (Christofk et al 2008b, Hitosugi 
et al 2009).  Cancer cells may revert to the fetal M2 isoform because the highly regulated M2 
isoform can switch between active and inactive forms, controlling the flow of glycolytic carbons 
between biosynthesis and mitochondrial ATP production during different phases of the cell cycle 
or different physiological contexts.  An inactive PKM2 would support increased biosynthesis 
during periods that require higher concentrations of triose phosphates for amino acid (serine, 
glycine, and cysteine), lipid (triacylglyerol, phospholipid, and sphingolipid), and nucleotide 
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synthesis.  In contrast, active pyruvate kinase promotes oxidative phosphorylation, and this 
ability to switch rapidly from biosynthesis to promoting ATP production may explain why 
PKM2 is selected for in all cancer cells studied. 
      Paradoxically, proliferating cells that selectively express the less active isoform of 
pyruvate kinase (M2) produce more lactate.  Human cancer cell lines engineered to express 
PKM1 produce less lactate than the same cells expressing PKM2 (Christofk et al 2008a).  Also, 
PKM2 inhibition by prolactin increases lactate content and stimulates proliferation in human cell 
lines (Varghese et al 2010).  One potential explanation for this paradox is that the overall 
increase in glycolytic flux results in higher flux through pyruvate kinase despite expression of 
the less active isoform.  Also, an alternative metabolism of phosphoenolpyruvate to pyruvate can 
compensate for decreased pyruvate kinase activity in proliferating cells, allowing for glucose 
conversion to pyruvate without producing ATP (Vander Heiden et al 2010).  Finally, lactate 
production regenerates NAD+, a cofactor necessary to maintain high glycolytic flux, suggesting 
that lactate production itself may facilitate faster glucose metabolism.       
 
Conclusions and perspectives  
Cell proliferation requires increased uptake of nutrients (e.g., glucose and glutamine), 
elevated flux through biosynthetic pathways (e.g., nucleotide, lipid, and protein biosynthesis), 
maintenance of metabolic intermediates (e.g., glucose-6-phosphate, fructose-6-phosphate, 
glyceraldehydes-3-phosphate, dihydroxyacetone phosphate, 3-phosphoglycerate and acetyl-CoA) 
and continued regeneration of cofactors needed to provide free energy or reducing equivalents 
for reactions (e.g., ATP, NADPH and NADH).  Aerobic glycolysis allows the cell to meet these 
requirements of proliferation, and this may be why aerobic glycolysis is a common feature of 
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many proliferating cells, including cancer cells.  Although aerobic glycolysis also generates 
lactate and ATP, these products are likely not the main reason for enhanced glucose metabolism.  
Accounting of ATP production by glycolysis versus oxidative phosphorylation has been done 
many times in various cells and tissues, and all have concluded that oxidative phosphorylation 
remains the main contributor of ATP in most cells under aerobic conditions.  An understanding 
of how cells meet the other requirements of proliferation is needed.  Which nutrients provide all 
the carbons, nitrogens, and other atoms necessary to double the mass of a cell?  How much does 
each nutrient contribute to biomass?  How is enough reducing power generated for cell 
maintenance and proliferation?  Which pathways provide the considerable amounts of NADPH 
required for lipid biosynthesis?  How does a cell balance the requirements of growth and 
homeostasis?  A comprehensive accounting of the complete metabolic requirements of a cell has 
never been done.  The technology exists to begin answering these questions and move forward in 
understanding metabolism in cancer and other proliferating cells.  Examining the requirements of 
cell growth in its entirety will shed new light on the role of aerobic glycolysis in cells.   
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Figure captions and Tables 
 
Figure 1.  Metabolic pathways active in proliferating cells.  This schematic represents our 
current understanding of how glycolysis, oxidative phosphorylation, the pentose phosphate 
pathway, and glutamine metabolism contribute to biomass precursors.  Enzymes that control 
critical steps and are often overexpressed or mutated in cancer cells are shown in blue.  
Nucleotides that can be incorporated into DNA and RNA are highlighted in light blue; 
representative lipids are highlighted in green; and nonessential amino acids are highlighted in 
orange.  Some key metabolites that serve as important precursors for biomass production are 
boxed. Glucose and glutamine, the major carbon sources in most proliferating cells, are shown; 
however, other metabolites can serve as carbon sources if available.  In the mitochondria, 
conversion between glutamate and α-ketoglutarate requires NAD(P)/NAD(P)H only if catalyzed 
by glutamate dehydrogenase.  
 
 
Figure 2.  Schematic showing the approximate contributions of glucose carbons and glutamine 
carbons and nitrogens to biomass, lactate, and CO2 in a proliferating cell. 
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Table 1.  Cofactor requirements for de novo nucleotide, amino acid, and lipid biosynthesis from 
indicated precursors.  Cofactors required for glucose import and precursor synthesis are not 
included.  Ribose-5-phosphate requires 2 NADP+ molecules if generated oxidatively from 
glucose; however, it can also be made non-oxidatively, and there is evidence that this is a major 
pathway used in at least some cancer cells (Boros et al 1998).  At least one NADPH is required 
for the reaction cycle involving thymidylate synthase (which uses 5,10-methylene-THF) in dTTP 
synthesis and this requirement is included.  Additional NADP(H) requirments for folate 
metabolites used in the synthesis of purine bases and amino acids can vary and are not included.  
Cofactor requirements for lipids that incorporate fatty acyl-CoA’s (e.g., phospholipids, 
triacylglycerols, and sphingolipids) vary and are not included. 
 Metabolite Precursor ATP NAD+ NADPH GTP 
NUCLEOTIDES 
ATP Ribose-5-P 8 -- -- 1 
GTP Ribose-5-P 9 1 -- -- 
CTP Ribose-5-P 6 1 -- -- 
UTP Ribose-5-P 4 1 -- -- 
dATP Ribose-5-P 8 -- 1 1 
dGTP Ribose-5-P 9 1 1 -- 
dCTP Ribose-5-P 6 1 1 -- 
dTTP Ribose-5-P 7 1 2 -- 
NONESSENTIAL 
AMINOACIDS 
Cysteine 3-Phosphoglycerate -- 1 -- -- 
Glycine 3-Phosphoglycerate -- 1 -- -- 
Serine 3-Phosphoglycerate -- 1 -- -- 
Alanine Pyruvate -- -- -- -- 
Asparagine Oxaloacetate 1 -- -- -- 
Aspartate Oxaloacetate -- -- -- -- 
Glutamate α-Ketoglutarate -- -- --* -- 
Glutamine α-Ketoglutarate 1 -- --* -- 
Proline α-Ketoglutarate 1 -- 2* -- 
Arginine α-Ketoglutarate 1 -- 1* -- 
Tyrosine Phenylalanine -- -- -- -- 
LIPIDS 
Palmitoyl-
CoA Acetyl-CoA 8 -- 14 -- 
Cholesterol Acetyl-CoA 18 -- 26 -- 
*An additional NAD(P)H is required if the α-ketoglutarate to glutamate conversion is 
catalyzed by mitochondrial glutamate dehydrogenase. 
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Table 2.  Biosynthetic precursors that provide the carbons and nitrogens in NTPs and dNTPs.  
The majority of carbons in nucleotides are derived from 5-phosphoribosyl-α-pyrophosphate 
(PRPP), a metabolite derived from glycolytic intermediates.  Thus, glycolysis is a major carbon 
contributor to nucleotide biosynthesis.  
 
dNTP # Precursor Carbon contribution 
Nitrogen 
contribution 
ATP/ 
dATP 
 
1 5-Phosphoribosyl-α-pyrophosphate 5 -- 
2 N10-formyl-tetrahydrofolates 2 -- 
1 Bicarbonate 1 -- 
1 Glycine 2 1 
1 Aspartate -- 2 
2 Glutamines -- 2 
  Total 10 5 
GTP/ 
dGTP 
1 5-Phosphoribosyl-α-pyrophosphate 5 -- 
2 N10-formyl-tetrahydrofolates 2 -- 
1 Bicarbonate 1 -- 
1 Glycine 2 1 
1 Aspartate -- 1 
2 Glutamines -- 3 
  Total 10 5 
UTP/ 
CTP/ 
dCTP 
1 5-Phosphoribosyl-α-pyrophosphate 5 -- 
1 Bicarbonate 1 -- 
1 Aspartate 3 1 
1 Glutamine -- 1 
 Total 9 2 
dTTP 
1 5-Phosphoribosyl-α-pyrophosphate 5 -- 
1 Bicarbonate 1 -- 
1 Aspartate 3 1 
1 Glutamine -- 1 
1 5,10-methylene-tetrahydrofolate 1 1 
 Total 10 2 
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